Legal Proceedings and Contingencies (Details)	1 Months Ended		3 Months Ended	12 Months Ended
	Aug. 31, 2019 company	Jun. 30, 2016 investment_fund	May 31, 2019 company	Dec. 31, 2021 lawsuit claim	Dec. 31, 2021 class_action claim	Dec. 31, 2021 claim direct_purchaser	Dec. 31, 2021 end_payor_purchaser claim	Dec. 31, 2021 claim company	Dec. 31, 2021 claim investment_fund	Jun. 30, 2020 investment_fund
Generic drug pricing securities litigation in U.S. District Court of New Jersey
Legal Proceedings and Contingencies
Number of individual plaintiff lawsuits | lawsuit				1
Number of purported class actions | class_action					3
Elliott Associates, L.P.
Legal Proceedings and Contingencies
Number of claims pending | investment_fund										1
Number of parties to lawsuit (in investment funds) | investment_fund		5
Number of plaintiff claims dismissed | investment_fund									3
Prescription drug abuse litigation in state courts
Legal Proceedings and Contingencies
Number of claims pending | claim				251	251	251	251	251	251
Prescription drug abuse litigation
Legal Proceedings and Contingencies
Number of claims pending | claim				3,130	3,130	3,130	3,130	3,130	3,130
Bystolic antitrust litigation
Legal Proceedings and Contingencies
Number of generic companies with whom certain litigation related agreements were entered into | company								6
Humira Antitrust Litigation [Member]
Legal Proceedings and Contingencies
Number of individual putative class action lawsuit | company			12
AndroGel antitrust litigation, King Drug Co. of Florence, Inc. v. AbbVie Inc.
Legal Proceedings and Contingencies
Number of generic companies with whom certain litigation related agreements were entered into | company	3
Niaspan
Legal Proceedings and Contingencies
Number of individual plaintiff lawsuits | lawsuit				4
Number of purported class actions | class_action					2
Number of healthcare benefit providers acting as plaintiff in lawsuit						1	1